Is Entresto (sacubitril/valsartan) used in chronic kidney disease (CKD)?
Entresto (sacubitril/valsartan) is used for certain patients with heart failure. Whether someone with CKD can use it depends on how advanced their kidney disease is and how much potassium and kidney function (creatinine/eGFR) they have, because the medicine can affect kidney function and raise potassium.
How does CKD change the way clinicians dose Entresto?
Dosing and monitoring typically change in CKD because sacubitril/valsartan can:
- Affect kidney filtration and kidney function markers.
- Increase the risk of hyperkalemia (high potassium), which is more likely in CKD.
In practice, clinicians tend to start more cautiously and check labs more often in people with reduced kidney function.
What kidney-related side effects should CKD patients watch for?
Patients with CKD are usually counseled to watch for lab-related risks rather than specific symptoms alone, especially:
- Higher potassium.
- Worsening kidney function after starting or increasing doses.
- Low blood pressure, which can also worsen kidney perfusion in some patients.
If symptoms occur alongside abnormal labs—such as severe dizziness, fainting, or weakness—they should contact their clinician promptly.
Does Entresto worsen kidney function in CKD?
Entresto can change kidney function readings, and it can raise potassium. That does not automatically mean it is unsafe in CKD, but it does mean CKD patients generally need closer monitoring, particularly after initiation and after dose changes.
Are there alternatives for heart failure patients with CKD who can’t tolerate Entresto?
If a patient’s kidney function or potassium worsens, clinicians may switch heart-failure therapy to another regimen that fits the person’s renal status and lab results. The specific alternative depends on the type of heart failure (reduced vs preserved ejection fraction) and the patient’s potassium and eGFR.
What should you do if you have CKD and are considering Entresto?
Ask your clinician about:
- Your latest eGFR/creatinine trend and potassium level before starting.
- The plan for follow-up blood tests after starting (and after dose changes).
- Any other medications that also raise potassium (common examples include certain diuretics, ACE inhibitors/ARBs, and some kidney-protective agents), so interactions can be managed.
Where to check patent/exclusivity info (if you’re researching this drug)?
For patent and exclusivity research related to Entresto, DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/